Sutro Biopharma Stock
Develops protein therapeutics by using OCFS protein synthesis technology
Sign up today and learn more about Sutro Biopharma Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About Sutro Biopharma Stock
Sutro Biopharma is a biopharmaceutical company that uses its patented OCFS protein synthesis technology to develop next-generation protein therapeutics for the treatment of human disease. Sutro is applying its technology to the development of next-generation, non-native protein structures such as antibody fragments, single-chain antibodies, and other proteins with novel scaffolds. We are also working to provide novel functionalities to our core technology with a goal of further improving the therapeutic benefit of the products we make. Sutro Biopharma, Inc. has a 24,000 sq. ft facility located in South San Francisco, California. Our pilot facility houses 15-Liter fermentors, a 200-L fermentor, and related research, development and downstream activities to support the scale-up of protein therapeutic candidates.
Founder & Director
James R. Swartz
Vice President of Development and Manufacturing
Vice President of Research
Senior Director, Supply Chain and CMC Team Lead
Chief Business Officer
Chief Executive Officer, Board of Directors
William J. Newell
Chief Scientific Officer
Chief Financial Officer